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Abstract
Epithelial–mesenchymal transition (EMT) is prominent in
circulating tumor cells (CTC), but how it inﬂuences metastatic
spread in this setting is obscure. Insofar as blood provides
a speciﬁc microenvironment for tumor cells, we explored
a potential link between EMT and coagulation that may provide
EMT-positive CTCs with enhanced colonizing properties.
Here we report that EMT induces tissue factor (TF), a major
cell-associated initiator of coagulation and related procoagu-
lant properties in the blood. TF blockade by antibody or
shRNA diminished the procoagulant activity of EMT-positive
cells, conﬁrming a functional role for TF in these processes.
Silencing the EMT transcription factor ZEB1 inhibited both
EMT-associated TF expression and coagulant activity, further
strengthening the link between EMT and coagulation. Accord-
ingly, EMT-positive cells exhibited a higher persistance/survival
in the lungs of mice colonized after intravenous injection, a
feature diminished by TF or ZEB1 silencing. In tumor cells
with limited metastatic capability, enforcing expression of the
EMT transcription factor Snail increased TF, coagulant proper-
ties, and early metastasis. Clinically, we identiﬁed a subpopu-
lation of CTC expressing vimentin and TF in the blood of
metastatic breast cancer patients consistent with our observa-
tions. Overall, our ﬁndings deﬁne a novel EMT–TF regulatory
axis that triggers local activation of coagulation pathways
to support metastatic colonization of EMT-positive CTCs.
Cancer Res; 76(14); 1–13. 2016 AACR.
Introduction
The contribution of epithelial-to-mesenchymal transitions
(EMT) to CTCs biology has generated much interest (1–5). EMT
indeed provides epithelial tumor cells with enhanced migratory,
invasive, and survival abilities that participate in the liberation of
CTCs into the circulation (1, 2, 4, 5). A variety of EMT-inducing
extracellular signals and signaling pathways have been shown
to converge on the expression of EMT transcription factors includ-
ing the Snail and ZEB families, Twist, and E47 (6–8). These
transcription factors directly or indirectly repress or activate a
variety of EMT target genes to provide cells with enhanced
migratory and invasive ability, enhanced resistance to apoptosis
and senescence, and proangiogenic and proinﬂammatory activ-
ities. While their repressive activity on several epithelial genes has
been shown to involve a direct binding to promoter regions, their
ability to induce mesenchymal genes rather implicates indirect
and often unknown mechanisms (6–9). Closely linking EMT
to CTC, the expression of EMT mediators has been detected in
CTCs in animal models (2, 10) and in subpopulations of CTCs
isolated from cancer patients including breast cancer patients,
where they associate with poor clinical parameters and to the
particularly aggressive "triple-negative breast cancer" (TNBC)
subtype (5, 11, 12). It has thus been suggested that CTCs expres-
sing EMT features could represent a premetastatic population,
socalled metastasis-initiating cells (MIC). Phenotyping CTCs and
unravelling the mechanisms that enable them to accomplish
early steps of the metastatic spread (i.e., survival in the blood-
stream and early seeding in distant organs) are major challenges
for cancer research today.
Increasing literature today supports the involvement of coag-
ulation events in cancer progression (13, 14). The activation of
coagulation has indeed long been correlatedwithmalignancy and
the beneﬁcial impact of anticoagulants on cancer progression has
been demonstrated in animal models (15–17) and evaluated in
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clinical studies (18). More precisely in relation to early events
facilitating metastasis, studies using experimental models of
metastases have reported the rapid formation of ﬁbrin-platelet
richmicrothrombi in lung arterioles after intravenous injection of
mouse tumor cells (19, 20). Using mice with genetic defects in
distal hemostatic factors (prothrombin and ﬁbrinogen), Degen
and colleagues have clearly shown that coagulation events facil-
itate metastasis (13, 21).
Tissue factor (TF), a membrane-associated glycoprotein, has
emerged as the central player in the relationship between the
hemostatic system and cancer progression (13, 14, 22–26). TF
binds and activates coagulation factor FVII, which in turn triggers
the downstream coagulation cascade leading to thrombin gener-
ation and clot formation. Early screening studies have identiﬁed TF
as a differentially expressed gene in invasive cell lines such asMDA-
MB-231 breast cancer cell line. Enhanced TF expression has also
been found in a variety of solid tumors including breast cancers, in
which it associates with decreased overall survival or shorter
recurrence-free survival (26). TF is a downstream target of several
oncogenic pathways (RAS, HER2, MET, SHH), of the loss of tumor
suppressors such as PTEN or p53, and of transcriptional regulation
byNFkB, AP-1, or Egr-1 transcription factors (24, 25). Adding to its
expression at the cell surface, TF may also be released in micro-
particles harboring procoagulant activity (27). Experimental data
point to a determinant role of TF in facilitating both tumor growth
and metastasis, involving both coagulation-dependent and -inde-
pendentmechanisms. Indeed, in addition to its role in coagulation,
TF is directly involved, through its cytoplasmic tail, in signaling
events that modulate several cellular processes such as adhesion
and migration, apoptosis, and angiogenesis (22, 23, 26, 28).
We here explored the hypothesis that CTCs expressing EMT
traits could express high levels of TF, and harbor enhanced
procoagulant activity that could facilitate early metastasis.
Materials and Methods
Cell culture
Human breast cancer cell lines (MCF7, T47D, MDA-MB-468,
and Hs578T) were obtained from the ATCC. MDA-MB-231 and
A549 luciferase-expressing clones were purchased from Caliper
Life Sciences. The breast cancer PMC42-LA subline was obtained
from Dr. M.L. Ackland (Deakin University, Burwood, Australia;
ref. 29). Fibroblasts were isolated by explant from normal human
dermis. Human dermal lymphatic endothelial cells (HDLEC)
were obtained from PromoCell. All cell lines were used within
10 passages after authentication (STR DNA typing, Leibniz-Insti-
tute DSMZ), were mycoplasma free, and were cultured in DMEM
(Gibco) supplemented with 10% FCS. HDLEC were cultured in
EGM2-MV medium (Lonza).
For EMT induction, inducible cell lines were treated for
48 hours with 20 ng/mL recombinant EGF (Sigma, E9644) or
5 ng/mL recombinant TGFb (R&D Systems, 240-B).
For Snail induction in the doxycycline-inducible Snail system,
cells were seeded and treatedwith 250ng/mLdoxycycline (Sigma,
D9891) for different timeperiods. AdescriptionofMDA-MB-468-
iSnail generation is provided in Supplementary Materials and
Methods.
siRNA transfection
For ZEB1 and Snail siRNA transfection, cells were transfected
for 48 hours with RNAiMax (Thermo Fisher Scientiﬁc, Invitrogen)
and 20 nmol/L of the siRNA duplexes. For TF siRNA transfection
in MDA-MB-468-iSnail, cells were transfected by electroporation.
The siRNA sequences are listed in Supplementary Table S1.
shRNA transduction
MDA-MB-468 andMDA-MB-231 cells were transduced (GIGA-
Viral vectors platform, University of Liege, Liege, Belgium) with
shRNA lentiviral vectors against TF (TRCN#00000722348 and
TRCN#0000431323, Sigma-Aldrich) or control shRNA vectors
(Sigma-Aldrich #SHC005 and Addgene vector 1864).
qRT-PCR, Western blotting analyses, and ﬂow cytometry
qRT-PCR was performed as described previously (9). Primer
sequences are provided in Supplementary Table S2. Data are
expressed as the ratio of the mRNA of interest to GAPDH and,
for inducible cell lines, as fold induction in treated cells relative to
the untreated ones.
For Western blotting analyses, proteins were separated on 10%
SDS-PAGE and transferred to polyvinylidene diﬂuoride mem-
branes. The antibodies used are listed in Supplementary Table S3.
For the detection of cell surface–associated TF, cells were
detached with trypsin-EDTA, labeled with a FITC-conjugated
antibody against human TF (Supplementary Table S3), and
analyzed with the FACSCantoII.
IHC on human samples
Human breast tissues were obtained from 40 biopsies of ductal
invasive TNBCs from Reims University Hospital Biological
Resource Collection no. DC-2008-374 and staged according the
2009 WHO classiﬁcation. This study was approved by the Insti-
tutional Review Board of Reims University Hospital (Reims,
France). Tissue sections and antigen detection were performed
as described previously (see details for antibodies in Supple-
mentary Table S3; ref. 9). The results for immunohistochemical
detection of vimentin and TF were scored independently by two
pathologists who had no knowledge of the clinical data, as
follows: 0 ¼ no detection; 1 ¼ detection in <25% of tumor cells;
2¼ detection in 26%–50% of tumor cells; 3¼ detection in >50%
of tumor cells.
Clotting assay
For the visual clotting assay, whole blood was collected from
healthy donors on 3.2% sodium citrate. Cancer cells (10,000)were
suspended in 600 mL of serum-free DMEM (CaCl2 1.2 mmol/L)
and exposed to 300 mL of blood. Clot formation was monitored.
For blocking experiments, cancer cells were pretreated with anti-TF
blocking antibody (or a control IgG isotype) before the addition
of whole blood (Supplementary Table S3). All clotting experi-
ments were performed at least three times during an observation
period of 4 hours. Because the clotting times varied from one
blood donor to another, clot formation times from one experi-
ment are provided as a representative example.
Mice models
All animal studies were approved by the Animal Ethics Com-
mittee of the University of Liege (Liege, Belgium). BALB/c and
SCID mice (7 weeks of age) were purchased from Charles River
Laboratories.
After EMT induction or si/shRNA transfection, cells (1  105)
were injected in the tail vein. To quantify CTC persistence/early
seeding or metastasis formation, mice were sacriﬁced 24 hours or
3–5 weeks after intravenous injection, respectively. In long-term
Bourcy et al.
Cancer Res; 76(14) July 15, 2016 Cancer ResearchOF2
models, in vivo imaging was performed using an IVIS-200 imaging
system (Xenogen Caliper) as reported previously (10) and results
are expressed as the ratio of luminescence for each mouse to the
mean value of the reference group (mean  SEM). At the time of
sacriﬁce, whole blood was collected by intracardiac puncture. To
evaluate tumor cell contents in the blood and in the lungs, human
GAPDH levels were quantiﬁed by RT-nested qPCR, as described
previously (10). Double IHC for Ki67 and Von Willebrand Factor
(VWF) were performed on parafﬁn section of mouse lungs, as
described previously (10) and double immunoﬂuorescence against
vimentin and platelet CD42b was performed on frozen sections of
mouse lungs (see details for antibodies in Supplementary Table S3).
In some experiments, enoxaparin (Clexane, Sanoﬁ) was
injected subcutaneously at 10 mg/kg one hour before cell injec-
tion as described previously (17).
CTC analysis in blood samples from breast cancer patients
The Human Ethics Committee of University of Liege approved
the study protocol for CTCs, and all patients provided their
written informed consent.
CTC isolation [from 22 patients with metastatic breast cancer
(MBC), taken before starting a new line of anticancer therapy,
and from 10 healthy donors] and analysis were performed with
the ScreenCell cytokit (ScreenCell). Captured cells were ﬁxed
and permeabilized with methanol before being processed for a
triple immunostaining against vimentin, TF, and cytokeratins
(antibodies listed in Supplementary Table S3). The triple stain-
ing conditions were optimized using coverslip cultures of
different cell lines with known status of vimentin, TF, and
cytokeratin expression (Supplementary Fig. S1). Filters were
scanned with Nikon eclipse Ti-S microscope. An original auto-
matic detection program was developed in the laboratory to
detect automatically "pink" signals (corresponding to pan-
keratin labeling). An image detection program was implemen-
ted using the image analysis toolbox of Matlab R2014a
(8.3.0532) 64 bit (Mathworks, Natick) to establish colocations
and therefore to enumerate CTCs expressing TF and/or vimen-
tin. Results were validated by two independent examiners. Data
were analyzed to evaluate a potential correlation between the
presence of TFþ/vimentinþ CTCs and overall survival from the
date of the metastatic relapse (between 2010 and 2015).
Statistical analysis
Results are expressed as mean  SEM (n ¼ 3, for in vitro
experiments) or as median with interquartile range for MBC
patients. Statistical analyses were performed with Prism soft-
ware (GraphPad software). In vitro results expressed as fold
induction were analyzed with a two-tailed one-sample t test.
In vivo results were analyzed with a two-tailed Mann–Whitney
test. A P < 0.05 was considered statistically signiﬁcant. Associ-
ation between vimentin and TF expression in TNBCs was
studied using c2 or Fisher exact tests. Univariate analysis was
performed to evaluate the association between TFþ/vimentinþ
CTCs with overall survival using the Kaplan–Meier method and
compared with the log-rank test.
Results
EMT-positive cells express higher levels of TF
To examine a potential link between EMT and TF, we ana-
lyzed TF expression in different cellular models of EMT. We ﬁrst
compared the level of TF in two well-known noninvasive, EMT-
negative (EMT: MCF7 and T47D) and two invasive, EMT
positive (EMTþ: MDA-MB-231 and Hs578T) breast tumor cell
lines (Fig. 1A and B). qRT-PCR and Western blotting showed
that high TF expression was restricted to EMTþ cell lines dis-
playing high vimentin and low E-cadherin levels (Fig. 1A and
B). We next examined TF expression in three cellular models
that exhibit inducible EMT after growth factor treatment: EGF-
treated human mammary adenocarcinoma MDA-MB-468 cells
(Fig. 1A and B; refs. 10, 30), TGFb–treated human lung carci-
noma A549 cells (9), and EGF-treated human breast tumor
PMC42-LA cells (Supplementary Fig. S2A and S2B; refs. 29, 30).
EMT induction was conﬁrmed by qRT-PCR analysis and West-
ern blotting showing vimentin overexpression and E-cadherin
downregulation in all three EMT-induced cell lines (Fig. 1A and
B and Supplementary Fig. S2A and S2B). Regarding TF expres-
sion, it was clearly increased both at the RNA and protein levels
in all three systems induced to EMT.
Such an association between EMT and TF expression was also
validated on samples of TNBCs. TNBCs were selected because of
the well-described enrichment of EMT markers in this subtype
(31). We thus observed that vimentin expression by cancer cells
was associated with tumoral expression of TF (Fig. 1C).
EMT-positive cells display TF-dependent enhanced
procoagulant activity
Because cell surface TF is determinant for coagulation, we
examined cell surface–associated TF expression by ﬂow cytometry
in our cell systems (Fig. 2A). In agreement with the Western blot
results, these FACS analyses revealed that the EMTþ cells express-
ed more TF at the cell surface than the EMT cells.
Accordingly, the visual clot formation times of EMTþ cells
(MDA-MB-231 and Hs578T) were considerably shorter than
those of the EMT cells (MCF7 and T47D; Fig. 2B). Similarly,
growth factor–induced EMTþ cells formed a clot more rapidly
than their untreated controls (Fig. 2B). The visual clot formation
times of the different cell lines perfectly reﬂected the levels of TF.
Although we favored the visual clot formation assay that allowed
the comparison of many conditions, we conﬁrmed our results
using thromboelastometry (ROTEM; Supplementary Fig. S2C).
Conﬁrming the implication of EMT-induced TF expression in
initiating clotting, cell incubation with a TF antibody was shown
to strongly reduce clot formation in all EMTþ cells (Supplemen-
tary Fig. S3).
EMT transcription factors modulate TF expression and
coagulant properties
We further examined the potential contribution of two EMT
transcription factors (ZEB1 and Snail as the prototype of the ZEB
and Snail family, respectively) in the regulation of TF expression.
qRT-PCR showed that ZEB1 was expressed more strongly by the
EMTþ cell lines MDA-MB-231 and Hs578T than by the EMT cell
linesMCF7 and T47D, although this association was less clear-cut
for Snail (Fig. 3A). Furthermore, both ZEB1 and Snail were
induced upon growth factor induction of EMT in all 3 inducible
systems (Fig. 3A and Supplementary Fig. S4A) although the
induction of Snail in PMC42-LA cells treated with EGF did not
reach signiﬁcance.
Supporting a functional contribution of Snail and ZEB1 to TF
expression, siRNA against these two transcription factors were
found to drastically reduce TF protein levels both in EGF-treated
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and untreated MDA-MB-468 cells (Fig. 3B) and in the other cell
systems (Supplementary Fig. S4B). Because ZEB1 silencing was
stronger and was conserved in all cellular models, we focused
further on the effects of ZEB1 for silencing experiments and
conﬁrmed that ZEB1 siRNA transfection inhibited clot formation



















































































































TF expression and EMT status in different cell systems. A, qRT-PCR analyses of TF, vimentin and E-cadherin in EMT and EMTþ cell lines and in MDA-MB-468
cells not treated (Ctrl) or treated with EGF.  , P < 0.01. B, Western blotting analyses of TF, vimentin, and E-cadherin, and GAPDH protein as loading control.
C, illustrative microscopy images of vimentin and TF staining on serial sections in TNBCs. An EMT (left, no vimentin in tumor cells) and an EMTþ (right, presence
of vimentin in tumor cells) representative carcinoma are shown. Arrows, double negative or double positive tumor areas. Results of the statistical
Fisher test analysis are presented.
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Conversely, we used a model of MDA-MB-468 cells expres-
sing a doxycycline-inducible vector for Snail (MDA-MB-468-
iSnail) in which a strong expression of TF is achieved after
120 hours of doxycycline treatment, along with the induction
of vimentin expression (time course presented in Supple-
mentary Fig. S5). The induction of TF by Snail at 120 hours
also associated with enhanced coagulant properties (Fig. 3D
and E). Doxycycline-treatment of MDA-MB-468-iGFP control
cells did not modify TF expression or the coagulant activity
of the cells, showing that doxycycline treatment by itself
does not modify TF expression. In addition, transfecting a
siRNA against TF in the MDA-MB-468-iSnail diminished the
coagulant properties induced by Snail (Fig. 3E). These results
strongly suggest that the induction of coagulant properties by
Snail is mediated by its impact on TF rather than on other
Snail target genes.
EMTþ CTCs exhibit a higher survival/persistence in colonized
lungs
To examine further the impact of this identiﬁed EMT–TF
regulatory axis on early metastasis of EMTþ CTCs, we optimized
short-term models by injecting intravenously BALB/c mice that
were sacriﬁced 24 hours after injection. Using MDA-MB-468
and MDA-MB-231 cells, we ﬁrst appraised whether EMTþ cells
have higher abilities to survive/seed in the colonized organs
than EMT cells, and whether this is linked to TF expression by
using cells expressing a shRNA against TF that efﬁciently down-

























































Cell surface TF expression and procoagulant activity of EMTþ and EMT cell lines. A, ﬂow cytometry analyses of surface TF expression in EMT and EMTþ cell lines
and in inducible cell lines [not treated (Ctrl) or treated with EGF or TGFb]. A corresponding isotype antibody was used as a labeling control. B, clot assays
performed by incubating 10  103 cells with whole blood of healthy donors. Photographs were taken at a time that discriminated EMTþ and EMT cells.
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Regulation of TF by EMT transcription factors. A, qRT-PCR analyses of ZEB1 and Snail in EMT and EMTþ cell lines and in MDA-MB-468 cells not treated
(Ctrl) or treated with EGF.  , P < 0.05. B, Western blotting analyses of TF, Snail, and ZEB1 in MDA-MB-468 treated or not with EGF and transfected with two
nontargeting siRNA (Ctrl si1 or Ctrl si2), two siRNA against ZEB1 (ZEB1 si1 or ZEB1 si2), or two siRNA against Snail (Snail si1 or Snail si2). C, clot assays performed
with whole blood of healthy donors incubated with MDA-MB-468 (treated or not with EGF) and MDA-MB-231 transfected with Ctrl si1 or ZEB1 si1. D, Western
blotting analyses of TF, Snail, and ZEB1. E, clot assays performed with whole blood of healthy donors incubated with MDA-MB-468 iGFP or iSnail
treated or not with doxycycline (Dox) for 120 hours and transfected with Ctrl siRNA or TF siRNA.
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both cell systems (Supplementary Fig. S6A and S6B). MDA-
MB-468 transduced with one Ctrl sh or one TF sh were then
primed with EGF treatment in vitro before injection. RT-nested
qPCR against human GAPDH was performed to determine
tumor cell content. Human GAPDH was barely detectable in
the blood in all four groups of mice (data not shown), suggest-
ing that CTCs are rapidly cleared from the circulation. In
contrast, signiﬁcant amounts of human GAPDH were detected
in lung extracts and these levels were clearly higher in mice
injected with EGF-treated MDA-MB-468 (EMTþ) transduced
with Ctrl sh than in nontreated MDA-MB-468 Ctrl sh cells
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Figure 4.
Impact of TF and coagulation on CTC persistence in mouse models. A, RT-nested qPCR for human GAPDH performed on total RNA extracted from lungs of
BALB/c mice injected intravenously with MDA-MB-468 cells (treated or not with EGF; n ¼ 8, top) or MDA-MB-231 (n ¼ 8, bottom) transduced with Ctrl
shRNA or TF shRNA and collected 24 hours after injection. Double IHC against human Ki67 (black) and mouse VWF (red) performed on lung sections
from mice injected with the EGF-treated MDA-MB-468 group (top) or Ctrl shRNA MDA-MB-231 group (bottom). B, RT-nested qPCR for human GAPDH performed
on total RNA extracted from the lungs of BALB/c mice treated or not with 10 mg/kg of enoxaparin 1 hour before intravenous injection of EGF-treated MDA-MB-468
cells (n ¼ 11, top) or MDA-MB-231 (n ¼ 11, bottom).  , P < 0.01;  , P < 0.001. C, double immunoﬂuorescence against human vimentin (blue) and mouse
CD42b (platelets, red) performed on frozen lung sections from immunodeﬁcient mice injected with MDA-MB-231 and collected 24 hours after injection.
Nuclei were labeled with TO-PRO-3 (white).
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signiﬁcantly abrogated the observed increased cell persistence
associated with the induction of EMT by EGF. IHC against
human Ki67 (black) and mouse VWF (red) qualitatively con-
ﬁrmed the presence of isolated tumor cells in the pulmonary
microvasculature and parenchyma of mice injected with EGF-
treated Ctrl sh (Fig. 4A). Similar results were obtained with
MDA-MB-231 cells (Fig. 4A). These results thus showed that
EMTþ cells have the ability to undertake the early steps of
metastases (i.e., survival and early seeding) and implicate TF in
such properties.
Clearly implicating coagulation in these early metastatic pro-
cesses, a signiﬁcant decrease in tumor cell content was observed in
the lungs of mice pretreated with the anticoagulant enoxaparin
and then injected with EGF-treated MDA-MB-468 or MDA-MB-
231 (Fig. 4B). Also, double immunoﬂuorescence against mouse
CD42b (a platelet marker) and human vimentin revealed that
MDA-MB-231 cells colonizing the lungs were surrounded by
platelet-rich microthrombi (Fig. 4C) and transmission electron
microscopy further evidenced the presence of ﬁbrin ﬁbers around
these colonizing cells (Supplementary Fig. S7).
Strengthening the link between EMT, the TF/coagulation
axis, and early metastatic colonization, ZEB1 silencing was
clearly shown to diminish cell persistence both of EGF-induced
MDA-MB-468 cells (Fig. 5A) and of MDA-MB-231 (Fig. 5B).
Furthermore, using the MDA-MB-468-iSnail system demon-
strated a higher persistence in the lungs of the doxycycline-
induced cells expressing Snail than the untreated cells (Fig. 5C).
The transfection of a siRNA against TF diminished this Snail-
induced persistence in the lungs (Fig. 3E), conﬁrming the
implication of Snail-induced TF in this process and not other
Snail target genes.
These data taken together thus support the involvement of TF-
dependent and coagulation-dependentmechanisms in earlymet-
astatic colonization of EMTþ tumor cells.
To conﬁrm the ability of seeded cells to develop metastasis, we
examined further the impact of EMT and TF modiﬁcations on
overall long-termmetastasis formation. The luciferase-expressing
MDA-MB-231 cells silenced for TF or ZEB1 were thus intrave-
nously injected in SCID mice for 3–5 weeks to allow metastatic
growth. We observed that mice injected with control cells showed
a higher level of luciferase activity both in toto and in the dissected
lungs compared with mice injected with cells silenced for TF or
ZEB1 (Fig. 6A and D). RT-nested qPCR for human GAPDH
corroborated these observations (Fig. 6B and E). IHC for human
Ki67 conﬁrmed the presence of lung metastases in the control
group while smaller and fewermetastases were observed in the TF
or ZEB1-silenced groups (Fig. 6C and F). These results obtained
with long-termmousemodels are in agreementwith independent
literature showing the involvement of ZEB1 (6, 8) and TF on
metastasis development (13).
CTCs expressing vimentin and TF are present in the blood
samples of MBC patients
To provide clinical validation of our in vitro and animal obser-
vations, we looked for TF/vimentin expressing CTCs in the blood
of MBC patients. Patient details are provided in Supplementary
Table S4. Because of the known limitations in using existing
immunomagnetic isolation method based on the epithelial cell
surface antigen to analyze EMT-derived CTCs (32), we used
ScreenCell ﬁltration devices to enrich CTCs and performed a
triple immunoﬂuorescent labeling (pan-keratins, TF, vimentin).
Some cells strongly expressing keratins but not TF or vimentin
were found at a similar level both in healthy donors and cancer
patients that could represent circulating epithelial cells. In con-
trast, keratin-positive cells expressing TF, vimentin, or both were
found only in cancer patients and not in healthy donors, andwere
enumerated. Representative images of these three CTC pheno-
types present in blood samples of MBC patients are shown
in Fig. 7A. Most interestingly, a population of CTCs expressing
cytokeratins and both TF and vimentin was identiﬁed in 19 of
22 (86.3%) patients. A CTC population expressing cytokeratins
and TF but no detectable vimentin was also found in 81.8%of the
cancer patients. In contrast, CTCs expressing cytokeratins andonly
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Figure 5.
CTC persistence in mice injected with cancer cell lines modulated for ZEB1 or Snail expression. RT-nested qPCR for GAPDH performed on RNA extracted
from lungs of BALB/c mice injected intravenously for 24 hours with MDA-MB-468 cells (treated or not with EGF; n ¼ 10; A) or MDA-MB-231 (n ¼ 16) transfected
with Ctrl siRNA or ZEB1 siRNA (B) or MDA-MB-468 iSnail (treated or not with doxycycline) transfected with Ctrl siRNA or TF siRNA (n ¼ 14; C).  , P < 0.05;
 , P < 0.01;  , P < 0.001. Dox, doxycycline.
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(40.9%; Fig. 7B and C). Although a large-scale study is needed to
reﬁne the clinical value of this subpopulation of CTCs, it is
interesting to note that the presence of TFþ/vimentinþ CTCs
correlated with a shorter survival. The highest signiﬁcance (P ¼
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Metastasis formation in SCID mice injected
with MDA-MB-231 silenced for TF (A–C) or
ZEB1 (D–F) expression. A and D, In vivo
imaging analyses of SCID mice injected
intravenously with MDA-MB-231 cells 3–5
weeks after injections, and of collected
lungs (n¼ 7). B and E, RT-nested qPCR for
human GAPDH performed on total RNA
extracted from lungs (n¼ 7 for B and n¼ 5
for E).  , P < 0.01; , P < 0.001. C and F,
double IHCagainst humanKi67 (black) and
mouse VWF (red) performed on lung
sections. Arrows, metastatic foci.
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Patient ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Total CTCs 51 8 12 21 164 7 2 6 4 3 15 2 34 80 4 9 2 3 6 2 3 4
TF+ CTCs 29 6 5 14 145 4 0 4 3 2 10 0 19 51 4 9 1 1 3 0 0 2
Vimentin+ 
CTCs 4 0 1 0 0 0 0 0 1 0 3 0 0 1 0 0 0 1 1 0 1 1
TF+/vimentin+ 
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TF and vimentin expression in CTCs isolated from MBC patients. A, representative images of the triple immunostaining performed on ScreenCell
ﬁlters showing the CTC phenotypes found in MBC patients (pan-keratin, pink; TF, green; vimentin, red; DAPI, blue). B, quantitation of CTC phenotypes
in each patient. C, graph plot of CTC numbers found in MBC patients as a function of their phenotype (CTCs expressing only TF, only vimentin,
or both).  , P < 0.001. D, association between TFþ/vimentinþ CTCs and overall survival of MBC patients (cut-off point at 3 TFþ/vimentinþ
CTCs, Kaplan–Meier method with log-rank test).
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Discussion
We provide evidence that an EMT-induced pathway leading
to the overexpression of TF and corresponding procoagulant
properties contributes to the persistence/early metastatic colo-
nization of CTCs.
Despite early independent implications of both in carcinoma
metastasis, the link between EMT and TF has been largely unap-
preciated. Here TF was found to be overexpressed in association
with EMT in three different growth factor EMT-inducible cell
systems, and TF expression was highest in the invasive, EMTþ
MDA-MB-231 and Hs578T breast cancer cell lines. Strengthening
this EMT–TF axis, we further report the modulation of TF expres-
sion by well-known EMT transcription factors ZEB1 and Snail. In
support of our observations, Rak and colleagues reported
enhanced TF expression and release of TF-containing micropar-
ticles from human A431 cervical cancer cells induced to EMT
through EGFR activation or E-cadherin blockade. They showed
that xenografts of A431 cells also release TF into the bloodstream
and enhance overall coagulopathy compared with tumor-free
mice (33–35). Our data correlating vimentin and TF expression
in the biopsies of TNBCs further emphasizes a link between EMT
and TF expression in human tumor tissues. Most importantly, we
were able to validate this association between vimentin and TF
expression in a subpopulation of CTCs of MBC patients. If such a
TFþ/vimentinþ phenotype is seen in tumors, it could also be
acquired in the bloodstream. Accordingly, platelets have been
reported to induce EMT and TF expression in different types of
cancer cells (36, 37).
We further implicate this identiﬁed EMT–TF axis in early
metastasis of CTCs. Our data indeed show that EMT-induced TF
provides CTCs with enhanced survival/early seeding properties.
The observation that EMT-induced cells silenced for TF or ZEB1
were less persistent in the lungs of intravenously injectedmice and
that doxycycline-induced cells expressing Snail were more persis-
tent in the lungs of intravenously injected mice clearly supports a
causal role of EMT-induced TF in these early metastatic processes.
Corroborating these in vivo ﬁndings, shRNA/siRNA against TF or
TF-blocking antibodies strongly diminished the EMT-induced
in vitro procoagulant activity in all cellular models examined.
Our ﬁndings showing that the anticoagulant molecule enoxa-
parin decreased EMTþ cell persistence in the lungs, further con-
ﬁrmed the implication of the coagulation system in the process.
Although the impact of such EMT/TF axis on early metastatic
steps has never been reported, our data are generally supported by
reports demonstrating that TF favors metastasis. Targeting TF or
TF pathway with TF-antibodies or TF inhibitors accordingly
represents today a promising alternative therapeutic strategy for
cancer patients to the use of global anticoagulants, the routine use
of which is often associatedwith bleeding complications (26, 38–
40). Thus, the administration of TF-blocking antibodies in exper-
imental metastases models was shown to reduce short-term
persistence in colonized organs of B16 melanoma cells (39) or
of human pancreatic cancer cell lines BxPCR3 (41), as well as the
development of metastases by these two cell lines or MDA-MB-
231 cells (40). Similarly, siRNA against TF decreased lung
metastatic burden from intravenous-injected B16 melanoma
cells or from xenografts of human melanoma cells (42), while
overexpression of different TF constructs in human melanoma
cells enhanced the development of lung metastases in intrave-
nously injected SCID mice (43). Using mutant constructs of TF
that are unable to initiate the coagulation cascade, these authors
further revealed the importance of noncoagulant functions of TF
in metastatic growth (43). On the other hand, coagulation-
dependent effects of TF on metastases have been demonstrated
by the laboratory of J.L. Degen (Cincinnati Children's Hospital
Medical Center, Cincinnati, OH), who injected intravenously
tumor cellsmodiﬁed for TF expression inmicewith genetic defects
in distal hemostatic factors (prothrombin and ﬁbrinogen). They
thus revealed that TF supports metastasis through mechanisms
dependent on these distal hemostatic factors (13, 21).
Taken together, these observations suggest that both coagula-
tion-dependent and independent functions of TF therefore con-
tribute to the metastatic development, depending on the cellular
andmicemodels used, whereas coagulation-dependent functions
would more selectively support early metastatic steps. Such con-
clusions are also supported by our results obtained with the
enoxaparin-treated mice and by literature similarly reporting the
beneﬁcial impact of anticoagulants (15, 16) or of mice deﬁcient
for distal hemostatic factors (such as ﬁbrinogen; ref. 44) in short-
term experimental metastasis models using B16 or LLC cells.
The precise mechanisms by which coagulation events may
favor early persistence of CTCs in the colonized organs remain
elusive. Examining colonizing MDA-MB-231 cells 24 hours after
intravenous injection, we showed that cells are covered with
platelets and the presence of ﬁbrin ﬁbers around the cells was
evidenced by transmission electron microscopy, supporting the
ideaof the formationof a "protective cocoon" as proposed in early
work (19). In the light of the importance of CTC-associated TF
expression, it is possible that a local activation of the coagulation
cascade aroundCTCs plays amajor role in the formation of such a
ﬁbrin-rich pericellular network. This network could protect CTCs
against hostile signals including shear stress, modiﬁcations of
cell–cell and cell–matrix interactions, or immune cells, andwould
promote their metastatic potential. A mechanism involving a
protective role of ﬁbrin and/or platelets in NK-induced cytotox-
icity against tumor cells has, for instance, been demonstrated in
vitro and using NK-deﬁcient mice in experimental metastasis
assays by Degen and colleagues (21, 44–48). On the other hand,
NK-independent processes have also been evidenced (21), one of
which implicates the recruitment of monocytes/macrophages in
microthrombi favoring the establishment of so-called premeta-
static niches (49).
Interestingly, a new insight in the CTC ﬁeld is the identiﬁcation
of CTC clusters within the circulation and, which, althoughmuch
less prevalent than isolated CTCs, have been suggested to have
high metastatic potential (50). In the light of our results, it is
tempting to speculate that coagulation events could be implicated
in the formation or persistence of these clusters. Literature report-
ing xenografts in animal models has suggested that CTC clusters
arise from the fragmenting of primary tumor cell clumps rather
than from intravascular aggregation of single CTCs (50). Accord-
ingly, in our experimental metastasis models, colonizing EMTþ
cells in the lungswere rarely observed as clusters. In our samples of
CTCs isolated fromMBC patients, CTC clusters were actually only
occasionally observed. A study by Yu and colleagues, nevertheless
reported that breast CTCs expressing EMT traits occurred predom-
inantly as single cells but also asmulticellular clusters surrounded
by platelets (12). Though TF expression was not examined in this
study; this latter observation is in direct relationship with our
results and supports the idea that blood components could also
play a role in the survival of these clusters. Nevertheless, the data
to establish the potential implication of coagulation in the
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formation or survival of CTC clusters are still preliminary and
warrant further investigation.
Taken together, our data show that TF expression is upregu-
lated during EMT, providing tumor cells with enhanced coag-
ulant properties that facilitate early steps of their metastatic
colonization. Emphasizing the clinical relevance of our obser-
vations and the importance of EMT in the CTC compartment,
we identiﬁed CTCs expressing both vimentin and TF in 86.3%
of MBC patients while CTCs expressing only vimentin but not
TF were very rare. Our data thus support a mechanism by which
a local activation of coagulation triggered by enhanced TF
expression could trap EMTþ CTCs in platelet/ﬁbrin-micro-
thrombi, thereby favoring their survival and early seeding in
colonized organs. Targeting such a local mechanism could
represent an important extension to global anticoagulant strat-
egies against cancer.
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